SEC Form 4 · accession 0001140361-17-018662
Recro Pharma, Inc. · REPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stonepine Capital Management, LLC
10% Owner
Period of report
May 3, 2017
Accepted (ET)
May 5, 2017 · 6:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001588972
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F4 | May 3, 2017 | S | 13,808 | $7.7929 | D | 2,860,509 | I | See Notes |
| Common StockF1,F2,F3,F5 | May 3, 2017 | S | 2,340 | $7.7929 | D | 2,858,169 | I | See Notes |
| Common StockF6,F2,F3,F4 | May 4, 2017 | S | 172,000 | $7.691 | D | 2,686,169 | I | See Notes |
| Common StockF6,F2,F3,F5 | May 4, 2017 | S | 29,160 | $7.691 | D | 2,657,009 | I | See Notes |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This is a weighted average price. These securities were sold in multiple transactions at prices ranging from $7.7768 to $7.977. The Filers undertake to provide to the Issuer, any security holder of the issuer or the SEC staff, on request, information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 6 of this Form 4.
- F2The filers (the "Filers") are Stonepine Capital Management, LLC (the "General Partner"), Stonepine Capital, L.P. (the "Partnership"), Jon M. Plexico and Timothy P. Lynch. The General Partner is the general partner and investment adviser of investment funds, including the Partnership (collectively, the "Funds"). Mr. Plexico and Mr. Lynch are the General Partner's managers and control persons. These securities are held directly by the Funds for the benefit of their investors and are indirectly beneficially owned by the General Partner and Mr. Plexico and Mr. Lynch as the General Partner's control persons. The General Partner is filing this Form 4 for itself and the other Filers.
- F3The Filers are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Each Filer disclaims beneficial ownership of these securities except to the extent of that Filer's pecuniary interest therein.
- F4These securities were sold by the Partnership, which held 2,443,843 shares after the transaction on May 3 and 2,271,843 shares after the transaction on May 4.
- F5These securities were sold by the other Funds.
- F6This is a weighted average price. These securities were sold in multiple transactions at prices ranging from $7.69 to $7.838.